EMA reiterates positive recommendation for Eisai-Biogen’s Alzheimer’s drug
The EMA's human medicines committee last year backed Leqembi for a narrower set of patients than those evaluated in a late-stage…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Eisai
Elucidation of part of the mechanism by which Lecanemab slows the progression of Alzheimer’s
Measuring the Lec-PF concentration in CSF before and after lecanemab treatment may be useful in assessing the efficacy of…
Balancing cost and value with TCO
Total Cost of Ownership (TCO) is a crucial focus in the pharma industry, influencing sustainability and competitiveness.…
DIA’s India Annual Meeting to host discussions on evolving regulatory landscape
Subcontinent's regulators and stakeholders to also discuss patient safety, compliance, advanced therapies, and the impact of…
Shares of Japan’s Eisai tumble after EU rejects Alzheimer’s drug
EU regulator cites brain swelling risks, impacting Eisai and Biogen, and sparking concerns over global sales and market perception…
Eisai selects Medidata’s Clinical Data Studio to enhance clinical trial efficiency
AI-enhanced solutions will help Eisai accelerate data review and reconciliation by 80 per cent
Eisai and Biogen’s Leqembi launch in China marks turning point in Alzheimer’s treatment, says…
Leqembi is the only approved treatment in China that has shown efficacy in slowing the progression of Alzheimer’s by directly…
Eisai and EcoNaviSta collaborate to build a dementia ecosystem
Eisai and EcoNaviSta will conduct joint research aimed at the early detection of MCI and dementia even in healthy seniors, and…
Alzheimer’s drug Leqembi launched by Eisai, Biogen in China
China is the third country to launch LEQEMBI following the US and Japan
Merck, Eisai to discontinue late-stage study for skin cancer
Improvement in overall survival was one of the study's dual main goals, according to Merck and Eisai